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Poster Session II S333STAT1-deficient T cells were indeed deficient in Th1 cells
post-BMT. Relative to recipients of WT T cells, recipients of
STAT1-KO T cells had reduced capacity to secrete IFN-g
(46616664 vs. 26566281; p \ 0.03) and TNF-a (31546269 vs.
1872684; p \ 0.001) and reduced absolute numbers of splenic
CD4+IFN-g+ T cells (1461.9 vs .076.02; p \ 0.05) and
CD8+IFN-g+ T cells (4.161.2 vs. 0.86.1; p\0.05). As such, recip-
ients of STAT1-deficient T cells were indeed deficient in Th1-po-
larization post-BMT during cGVHD. Remarkably, relative to WT
T cell recipients, recipients of STAT-1 deficient T cells had in-
creased absolute numbers of post-BMT splenic CD4+IL-176 T
cells (0.260.05 vs 13.266.5.; p\ 0.05). These data indicate that
long-term post-BMT deficiency of Th1-type cells does not protect
against chronic GVHD, perhaps in part due to expansion of alterna-
tive pathogenic T cells such as the Th17 subset.500
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Introduction: Graft-versus-host disease (GVHD) remains a major
cause of morbidity and mortality in bone marrow transplant
(BMT) recipients. GVHD is classically described as T-cell lympho-
cytic infiltration followed by destruction of tissue caused by differ-
ences in HLA. However, treatments aimed at other components of
the immune system have been successful, questioning this paradigm.
The role of the complement system in GVHD is limited. In solid tu-
mor transplantation, activation of the complement system and link to
preformed anti-HLA antibodies in recipients has been associated
with rejection.We describe the evaluation of complement activation
in 53 patients with clinical GVHD in whom40 specimens of skin and
7/13 specimens of colon showed evidence ofGVHDby conventional
histochemical staining method. In addition, we analyzed 11 control
patients with normal colon biopsies. Analysis of complement fixation
was performed using C4d antibody staining method and was
analyzed using the Banff07 grading system where minimal staining
is denoted as positive in\10% of vessels and diffuse staining is pos-
itive in . 50% of vessels. Histology of GVHD was correlated with
C4d deposition. Statistical analysis using Fisher’s exact test was
performed between groups and with controls.
Results: Thirty-four of forty skin biopsies were evaluable for C4d
deposition (6 specimens showing extensive background deposition
were excluded). Twenty-one of thirty-four specimens showed C4d
staining (11 minimal, 9 focal, and 1 diffuse). Twelve of the thirteen
colon biopsies showed C4d staining (2 minimal, 4 focal, and 6 dif-
fuse). Of the 11 control colon biopsies, 10 were negative for C4d
and 1 showed minimal staining. In the cohort that showed clinical
GVHD not pathologically confirmed, 6/6 showed C4d staining.
The difference in C4d staining between the GVHD of the colon
and colon control specimens was statistically significant using
a Fisher’s exact test (p-value 5 0.00000177). In addition, there was
statistical difference between Cd4 staining in clinical GVHD vs.
controls with a p value of 0.0000127.
Conclusion: Our results demonstrate that most patients with clini-
cal GVHD showed vascular staining for C4d. Clinical GVHD and
C4d deposition were closely correlated and statistically different
from controls. This may indicate that C4d positivity is a more
sensitive marker in detecting GVHD of the colon than classic
GVHD histological evaluation.501
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ment for acute GVHD (aGVHD) following allogeneic hematopoi-
etic stem cell transplantation (AlloHSCT). Some patients with
aGVHD receive high-dose (HD) corticosteroids for $ 2 months
for a variety of reasons. Morbidities related to long term corticoste-
roid use are well recognized, however, the impact of dosing and
treatment duration on survival has not been fully evaluated in the
post-AlloHSCT setting.
Methods: From 1998 to 2009, 272 patients with AlloHSCT were
treated with corticosteroids between post-transplant days 30 and
100 at a single academic institution. Patients in HD group received
$ 30 mg prednisone daily for$ 2 months, whereas those in the low-
dose (LD) corticosteroid group received\ 30 mg at some point in
this interval or $ 30 mg for\ 2 months. Relapse-free (RFS) and
overall survival (OS) were compared between corticosteroid groups.
Cox proportional hazards analysis identified prognostic factors.
Results:HD (n5 98) and LD (n5 174) groups were similar in dis-
tribution of demographic characteristics, comorbidity index, diagno-
sis, number of previous chemotherapies and conditioning regimen
(all p $ 0.3). HD group had more MUD AlloHSCT (p 5 0.05)
and higher-grade aGVHD (p\ 0.001). Malignancy relapse in HD
and LD groups was 24% and 36%, whereas overall mortality was
59% and 55% respectively. Non-relapse mortality tended to be
higher (HR 5 1.5; 95% CI, 1.0-2.3) in HD group. No significant
association was detected between the HD corticosteroid use and
infection-related mortality (p 5 0.1), relapse mortality (p 5 0.2),
RFS (p5 0.8), or OS (p5 0.4). Multivariable analysis of non-relapse
mortality demonstrated no independent prognostic significance of
HD corticosteroid use (HR 5 1.3; 95% CI, 0.8-2) after adjustment
for comorbidity index (HR 5 2 for high vs. low HCT-CI; 95% CI,
0.8-2), source of hematopoietic stem cells (HR 5 2.3 for peripheral
vs. bone marrow; 95%CI, 1.3-4.1) and grade of aGVHD (HR5 1.3
per 1 grade increase; 95% CI, 1.1-1.6).
Conclusions: Using HD corticosteroids for $ 2 months did not
appear to have an independent impact on patient survival following
AlloHSCT and therefore it may be safe to use as necessary for
aGVHD control. The association of HD steroids with non relapse
mortality appears to be related to worse aGVHD.502
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Total Lymphoid Irradiation and Anti-Thymocyte Serum (TLI/
ATS) conditioning induces potent donor-host tolerance and
GVHD protection via induction of donor CD4+CD25+Foxp3+
Treg after bone marrow transplantation (BMT) (Pillai et al, Blood
2009). Whereas total body irradiation (TBI) at doses as low as 400
cGy associate with lethal acute GVHD after MHC-mismatched
BMT, TLI exposes GVHD target organs to a cumulative radiation
dose of 2400 to 4080 cGy, without GVHD. We investigated the
role of radiation exposure to specific anatomic areas in tolerance in-
duction after TLI/ATS + BMT. Wild-type (WT) BALB/c (H-2d)
hosts received infusion of 50 x 106 bone marrow + 60 x 106 spleno-
cytes from WT C57BL/6 (H-2b) donors (BMT) following 5 doses
of rabbit ATS + 10 doses (240 cGy each2400 cGy total) of fraction-
atedTBI, TLI, or TLIwith lead shielding of specific regions, includ-
ing TLI with focal thymic shielding (TLI-FTS). Day 6 H-
2Kb+CD8+ and H-2Kb+CD4+CD25neg effector cell and H-
2Kb+CD4+Foxp3+ Treg accumulation was quantified in target or-
gans, and GVHD scoring performed on histopathologic sections.
Positive controls included WT BALB/c hosts receiving ATS + sin-
gle-dose 800cGy TBI (PC-1) or ATS + 400 cGy TBI (PC-2) and
50 x 106 bone marrow + 60 x 106 splenocytes from C57BL/6 donors.
Negative controls received 800cGy TBI and 50 x 106 bone marrow
fromWTC57BL/6 (NC-1) or ATS alone + BMT (NC-2). All frac-
tionated TBI hosts died during conditioning with histopathologic
systemic radiation toxicity. In TLI/ATS hosts at day 6 after BMT,
accumulation of H-2Kb+TCR+CD8+ cells was strongly suppressed
in colon, MLN, and spleen (p\0.01), with increased accumulation
of donor Treg (p\0.01) compared to PC-1 controls. Mean colonic
